iPSC-Derived Hepatocytes as a Platform for Disease Modeling and Drug Discovery
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The liver is one of the largest organs in the body and is responsible for a diverse repertoire of metabolic processes. Such processes include the secretion of serum proteins, carbohydrate and lipid metabolism, bile acid and urea synthesis, detoxification of drugs and metabolic waste products, and vitamin and carbohydrate storage. Currently, liver disease is one of the most prevalent causes of mortality in the USA with congenital liver defects contributing to a significant proportion of these deaths. Historically the study of liver disease has been hampered by a shortage of organ donors, the subsequent scarcity of healthy tissue, and the failure of animal models to fully recapitulate human liver function. In vitro culture of hepatocytes has also proven difficult because primary hepatocytes rapidly de-differentiate in culture. Recent advances in stem cell technology have facilitated the generation of induced pluripotent stem cells (iPSCs) from various somatic cell types from patients. Such cells can be differentiated to a liver cell fate, essentially providing a limitless supply of cells with hepatocyte characteristics that can mimic the pathophysiology of liver disease. Furthermore, development of the CRISPR-Cas9 system, as well as advancement of miniaturized differentiation platforms has facilitated the development of high throughput models for the investigation of hepatocyte differentiation and drug discovery. In this review, we will explore the latest advances in iPSC-based disease modelling and drug screening platforms and examine how this technology is being used to identify new pharmacological interventions, and to advance our understanding of liver development and mechanisms of disease. We will cover how iPSC technology is being used to develop predictive models for rare diseases and how information gained from large in vitro screening experiments can be used to directly inform clinical investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
Vascularized and functional human liver from an iPSC-derived organ bud transplant
Takebe, T., Sekine, K., Enomura, M., Koike, H., Kimura, M., Ogaeri, T., Zhang, R.-R., Ueno, Y., Zheng, Y.-W., Koike, N., et al. (2013) · Nature · doi:10.1038/nature12271 · Cited by 2,170 · cited 1×
“Hepatic organoids derived from iPSCs have been developed by combining hepatic progenitor cells with human umbilical vein endothelial cells and human mesenchymal stem cells (51).”
MethodHighly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells
Si-Tayeb, K., Noto, F. K., Nagaoka, M., Li, J., Battle, M. A., Duris, C., North, P. E., Dalton, S., & Duncan, S. A. (2010) · Hepatology · doi:10.1002/hep.23354 · Cited by 1,282
Self-citationArrowsmith, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439 · Cited by 622
Generation of human induced pluripotent stem cells from urine samples
Zhou, T., Benda, C., Dunzinger, S., Huang, Y., Ho, J. C., Yang, J., Wang, Y., Zhang, Y., Zhuang, Q., Li, Y., et al. (2012) · Nature Protocols · doi:10.1038/nprot.2012.115 · Cited by 614
A High-Efficiency System for the Generation and Study of Human Induced Pluripotent Stem Cells
Maherali, N., Ahfeldt, T., Rigamonti, A., Utikal, J., Cowan, C., & Hochedlinger, K. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.08.003 · Cited by 563
Hay, D. C., Zhao, D., Fletcher, J., Hewitt, Z. A., McLean, D., Urruticoechea-Uriguen, A., Black, J. R., Elcombe, C., Ross, J. A., Wolf, R., et al. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0718 · Cited by 441
Orchestrating liver development
Gordillo, M., Evans, T., & Gouon-Evans, V. (2015) · Development · doi:10.1242/dev.114215 · Cited by 375
Organotypic liver culture models: meeting current challenges in toxicity testing
LeCluyse, E. L., Witek, R. P., Andersen, M. E., & Powers, M. J. (2012) · Critical Reviews in Toxicology · doi:10.3109/10408444.2012.682115 · Cited by 363
Guo, L., Dial, S., Shi, L., Branham, W., Liu, J., Fang, J.-L., Green, B., Deng, H., Kaput, J., & Ning, B. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035873 · Cited by 348
Identification of small molecules for human hepatocyte expansion and iPS differentiation
Shan, J., Schwartz, R. E., Ross, N. T., Logan, D. J., Thomas, D., Duncan, S. A., North, T. E., Goessling, W., Carpenter, A. E., & Bhatia, S. N. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1270 · Cited by 254
Self-citationIn Vitro Expansion of Primary Human Hepatocytes with Efficient Liver Repopulation Capacity
Zhang, K., Zhang, L., Liu, W., Ma, X., Cen, J., Sun, Z., Wang, C., Feng, S., Zhang, Z., Yue, L., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.10.018 · Cited by 252
Maetzel, D., Sarkar, S., Wang, H., Abi-Mosleh, L., Xu, P., Cheng, A. W., Gao, Q., Mitalipova, M., & Jaenisch, R. (2014) · Stem Cell Reports · doi:10.1016/j.stemcr.2014.03.014 · Cited by 195 · cited 1×
“Screens using specific classes of compounds have also been used to identify optimum efficacy from families of drugs (80, 81) as well as identify novel small molecules for the treatment of congenital liver disease (61, 70, 79) (Table 2).”
BackgroundHeslop, J. A., Rowe, C., Walsh, J., Sison-Young, R., Jenkins, R., Kamalian, L., Kia, R., Hay, D., Jones, R. P., Malik, H. Z., et al. (2017) · Archives of Toxicology · doi:10.1007/s00204-016-1694-y · Cited by 141
Molecular Obstacles to Clinical Translation of iPSCs
Tapia, N., & Schöler, H. R. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.06.017 · Cited by 141
Richert, L., Liguori, M. J., Abadie, C., Heyd, B., Mantion, G., Halkic, N., & Waring, J. F. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.007708 · Cited by 136
Ng, S. S., Saeb-Parsy, K., Blackford, S. J. I., Segal, J. M., Serra, M. P., Horcas-Lopez, M., No, D. Y., Mastoridis, S., Jassem, W., Frank, C. W., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.07.043 · Cited by 133
Park, K.-M., Hussein, K. H., Hong, S.-H., Ahn, C., Yang, S.-R., Park, S.-M., Kweon, O.-K., Kim, B.-M., & Woo, H.-M. (2016) · Tissue Engineering Part A · doi:10.1089/ten.tea.2015.0313 · Cited by 113
Carpentier, A., Nimgaonkar, I., Chu, V., Xia, Y., Hu, Z., & Liang, T. J. (2016) · Stem Cell Research · doi:10.1016/j.scr.2016.03.009 · Cited by 90
Cited by
The strategies and techniques of drug discovery from natural products
Zhang, L., Song, J., Kong, L., Yuan, T., Li, W., Zhang, W., Hou, B., Lu, Y., & Du, G. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107686 · Cited by 313
Revolutionizing Disease Modeling: The Emergence of Organoids in Cellular Systems
Silva-Pedrosa, R., Salgado, A. J., & Ferreira, P. E. (2023) · Cells · doi:10.3390/cells12060930 · Cited by 84
“Proof-of-concept studies revealed the efficacy of these cells in drug development, highthroughput drug screening, and modeling liver diseases and viral and parasitic infections, such as malaria [44,45].”
BackgroundKannan, S., Farid, M., Lin, B. L., Miyamoto, M., & Kwon, C. (2021) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1009305 · Cited by 52
Microfluidic Liver-on-a-Chip for Preclinical Drug Discovery
Fu, J., Qiu, H., & Tan, C. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041300 · Cited by 42
Rezvani, M., Vallier, L., & Guillot, A. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.01.014 · Cited by 34
Metadata
- Authors
- Corbett, J. L., & Duncan, S. A.
- Venue
- Frontiers in Medicine
- Publisher
- Frontiers Media SA
- Published
- 2019-11-15
- Volume
- 6
- Pages
- 265-265
- ISSN
- 2296-858X (ISSN-L)
- OpenAlex
- W2986914591
- Cited by
- 138
- References
- 19
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.